MENARINI RICERCHE SPA

Their core work

Menarini Ricerche is the clinical research division of Menarini Group, one of Italy's largest pharmaceutical companies, specializing in oncology and hematology. Their H2020 work centers on contributing pharmaceutical and clinical expertise to large European public-private partnerships studying blood cancers — leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. Within the HARMONY Alliance, they help build and use big data platforms that aggregate real-world patient data from across Europe to identify better treatment outcomes for hematological malignancies. More broadly, they bridge clinical trial expertise with translational research, connecting molecular genetic findings to commercial drug development pathways.

What they specialise in

How they've shifted over time

In the 2017–2019 period (HARMONY), Menarini Ricerche's focus was disease-centric and data-collection-oriented: building patient registries and a big data platform covering specific blood cancer subtypes — leukemia, lymphoma, MDS, multiple myeloma, and childhood cancers. By the 2020–2024 phase (HARMONY PLUS), the language shifted decisively toward translational medicine, molecular genetics, and digital health outcomes, alongside the appearance of "business model" as an explicit keyword. This trajectory points to an organization that first established the evidence base and is now working on converting that evidence into actionable, commercially viable healthcare decisions.

Menarini Ricerche is moving from data platform contributor toward translational and commercial application of hematology big data, making them an increasingly relevant partner for projects at the junction of real-world evidence and drug development or health technology assessment.

How they like to work

Menarini Ricerche participates exclusively as a consortium partner — they have never led an H2020 project — suggesting they contribute specialist pharmaceutical and clinical expertise within large, multi-partner alliances rather than driving research agendas independently. Both their projects belong to the same HARMONY family, indicating deep, long-term commitment to a single major alliance rather than broad portfolio diversification. Their engagement in consortia with 57 unique partners across 13 countries reflects comfort operating in complex, multi-stakeholder European public-private partnerships.

Menarini Ricerche has built connections with 57 distinct partners across 13 countries through just two projects, reflecting the exceptional scale of the HARMONY Alliance — one of Europe's largest IMI-funded public-private partnerships in hematology. Their network is pan-European and heavily concentrated in the health and pharmaceutical research ecosystem.

What sets them apart

Menarini Ricerche brings the rare combination of industrial pharmaceutical scale and focused hematological oncology expertise to European research consortia — they are not a generalist pharma company but a dedicated research unit with deep specialization in blood cancers and real-world evidence generation. As part of the Menarini Group (Italy's largest pharma company by revenue), they carry credibility and resources that academic or SME partners cannot match in late-stage translational work. For a consortium needing a pharmaceutical industry anchor in oncology, particularly one connecting clinical data to product development, they are a proven and well-networked choice.

Highlights from their portfolio

• HARMONY
  A flagship IMI public-private partnership (2017–2023) that created Europe's largest big data platform for hematological malignancies, involving dozens of partners across academia, industry, and patient organizations.
• HARMONY PLUS
  The 2020–2024 extension of HARMONY, expanding into molecular genetics and translational medicine and introducing explicit business model development — demonstrating sustained, evolving commitment to the alliance.